Early Access — free while we kick the tires
EdgarHawk

MCCOLLUM JAMES W

Director

Director
1 filing analyzed · 1 company · Latest 2025-11-10

Companies

Company Buys Sells Direction
LENZ Therapeutics, Inc. LENZ 1 0 Net buying

Activity

November 2025
medium
Buy
10,500 shares
$239,278
Significance 6/10

Director James W. McCollum buys 10,500 shares of LENZ at $22.79; stock down 52.7% from 52-week high amid unprofitability.

Director James W. McCollum purchased 10,500 shares at $22.79 on 2025-11-07, representing his first position in LENZ and totaling $239,278.20. This purchase occurs while the stock is down 52.7% from its 52-week high of $49.05 and has declined 40.2% over the past 30 days. Notably, McCollum's cross-ticker track record shows strong past execution (1 prior buy with 90d return of +48.7%), and his one prior trade at LENZ (a buy on 2024-05-13) proved well-timed, generating +48.7% over 90 days. However, the company's fundamentals remain challenged: it is unprofitable with a net income of $-16,700,000.00 against quarterly revenue of $12,500,000.00. The timing of this accumulation into a depressed price environment, coupled with McCollum's demonstrated track record of successful timing on LENZ, may signal conviction in the company's recovery prospects, yet the persistent unprofitability and recent sharp drawdown warrant close monitoring of subsequent quarters for signs of operational improvement.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access